AKT1 and cancer: HER3 is a key activator of PI3K/AKT and its inhibition has recently been studied alone and in combination with other agents (cetuximab, irinotecan, and paclitaxel) for the treatment of several cancers including NSCLC, breast, colon, head and neck, and ovarian.